» Articles » PMID: 10446910

Transcriptional Activation of E2F1 Gene Expression by 17beta-estradiol in MCF-7 Cells is Regulated by NF-Y-Sp1/estrogen Receptor Interactions

Overview
Journal Mol Endocrinol
Date 1999 Aug 14
PMID 10446910
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

17beta-Estradiol (E2) stimulated proliferation and DNA synthesis in MCF-7 human breast cancer cells, and this was accompanied by induction of E2F1 mRNA and protein levels. Analysis of the E2F1 gene promoter showed that the -146 to -54 region was required for E2-responsiveness in transient transfection assays, and subsequent deletion/mutation analysis showed that a single upstream GC-rich and two downstream CCAAT-binding sites were required for transactivation by E2. Gel mobility shift assays with multiple oligonucleotides and protein antibodies (for supershifts) showed that the -146 to -54 region of the E2F1 gene promoter bound Sp1 and NF-Y proteins in MCF-7 cells. The estrogen receptor (ER) protein enhanced Sp1 interactions with upstream GC-rich sites, and interactions of ER, Sp1, and ER/Sp1 with downstream DNA bound-NF-Y was investigated by kinetic analysis for protein-DNA binding (on- and off-rates), coimmunoprecipitation, and pulldown assays using wild-type and truncated glutathione S-transferase (GST)-Sp1 chimeric proteins. The results showed that Sp1 protein enhanced the Bmax of NF-Y-DNA binding by more than 5-fold (on-rate); in addition, the Sp1-enhanced NF-Y-DNA complex was further stabilized by coincubation with ER and the rate of dissociation (t1/2) was decreased by approximately 50%. Sp1 antibodies immunoprecipitated [35S]NF-YA after coincubation with unlabeled Sp1 protein. Thus, transcriptional activation of E2F1 gene expression in MCF-7 cells by E2 is regulated by multiprotein ER/Sp1-NF-Y interactions at GC-rich and two CCAAT elements in the proximal region of the E2F1 gene promoter. This represents a unique trans-acting protein complex in which ligand-dependent transactivation by the ER is independent of direct ER interactions with promoter elements.

Citing Articles

Targeting unique ligand binding domain structural features downregulates DKK1 in Y537S ESR1 mutant breast cancer cells.

Young K, Hancock G, Fink E, Zigrossi A, Flowers B, Cooper D Breast Cancer Res. 2025; 27(1):10.

PMID: 39825366 PMC: 11742495. DOI: 10.1186/s13058-024-01945-z.


Roles of miR-20a-5p in breast cancer based on the clinical and multi-omic (CAMO) cohort and in vitro studies.

Tylden E, Delgado A, Lukic M, Moi L, Rasmussen Busund L, Pedersen M Sci Rep. 2024; 14(1):25022.

PMID: 39443510 PMC: 11499649. DOI: 10.1038/s41598-024-75557-0.


Targeting Unique Ligand Binding Domain Structural Features Downregulates DKK1 in Y537S Mutant Breast Cancer Cells.

Young K, Hancock G, Fink E, Zigrossi A, Flowers B, Cooper D Res Sq. 2024; .

PMID: 38978585 PMC: 11230492. DOI: 10.21203/rs.3.rs-4542467/v1.


Targeting Unique Ligand Binding Domain Structural Features Downregulates DKK1 in Y537S Mutant Breast Cancer Cells.

Young K, Hancock G, Fink E, Zigrossi A, Flowers B, Cooper D bioRxiv. 2024; .

PMID: 38854123 PMC: 11160638. DOI: 10.1101/2024.05.28.596307.


The antidepressant imipramine inhibits breast cancer growth by targeting estrogen receptor signaling and DNA repair events.

Timilsina S, Rajamanickam S, Rao A, Subbarayalu P, Nirzhor S, Abdelfattah N Cancer Lett. 2022; 540:215717.

PMID: 35568265 PMC: 10313451. DOI: 10.1016/j.canlet.2022.215717.